ONC201 in Treating Patients With Relapsed or Refractory Acute Leukemia or High-Risk Myelodysplastic Syndrome
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
PedAL BCU, LLC
Sumitomo Pharma America, Inc.
AstraZeneca
Ossium Health, Inc.
City of Hope Medical Center
M.D. Anderson Cancer Center
Sanofi
Stanford University
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Instituto Nacional de Cancer, Brazil
AbbVie
Astex Pharmaceuticals, Inc.
Columbia University
Indiana University
Shenzhen TargetRx Co., Ltd.
University Hospital, Basel, Switzerland
Indiana University
Bellicum Pharmaceuticals
Bellicum Pharmaceuticals
University of Nebraska
Fate Therapeutics
Memorial Sloan Kettering Cancer Center
Bellicum Pharmaceuticals
Bellicum Pharmaceuticals
Chinese PLA General Hospital
Federal Research Institute of Pediatric Hematology, Oncology and Immunology
Gamida Cell ltd
Novartis
M.D. Anderson Cancer Center
National Cancer Institute (NCI)
Novartis
Novartis
Novartis
University Health Network, Toronto
Gamida Cell ltd
Masonic Cancer Center, University of Minnesota
National Institutes of Health Clinical Center (CC)
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Fred Hutchinson Cancer Center
Mirror Biologics, Inc.
Fred Hutchinson Cancer Center
Fred Hutchinson Cancer Center
Alliance for Clinical Trials in Oncology
Washington University School of Medicine
National Institutes of Health Clinical Center (CC)
Stanford University
Masonic Cancer Center, University of Minnesota